media – Page 5 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

The approval of telpopril monotherapy for type 2 diabetes has driven an upgrade in the management paradigm

　　According to this newspaper, in current clinical practice, the treatment of type 2 diabetes often relies heavily on the traditional approach of “gradually increasing medication.” Many patients only enter a more potent treatment phase after their blood sugar has been poorly controlled for a long time and the risk of complications has gradually accumulated. 　　However, in recent years, discussions surrounding early diabetes management have been undergoing a significant shift. A growing body of research suggests that the choice of treatment starting point not only affects short-term glycemic control but also profoundly relates to patients’ long-term complication risk and overall prognosis. Clinical management strategies for type 2 diabetes are shifting from a “late-stage reinforcement” approach to a new paradigm of “intervention at the starting point.” 　　February 11th, ReiThe innovative dual-target drug Mufengda® (Telborpeptide Injection) has been approved by the China National Medical Products Administration for monotherapy in adults with type 2 ...
- Source: drugdu
- 69
- February 13, 2026
Oral insulin launch fails; China Resources Pharmaceutical plans to sell Tianmai Biotechnology

On February 9, China Resources Pharmaceutical (03320.HK) issued an announcement on the Hong Kong Stock Exchange, stating that its wholly-owned subsidiary, China Resources Pharmaceutical Investment Co., Ltd., plans to sell its 17.87% stake in Hefei Tianmai Biotechnology Development Co., Ltd. (hereinafter referred to as “Tianmai Biotechnology”) through a public listing on the Shanghai United Assets and Equity Exchange, with a listing price of RMB 1.42 billion. Looking back at the history of cooperation between China Resources Pharmaceutical and Tianmai Biotechnology, their partnership began in 2016, when the number of diabetes patients in China continued to rise, leading to a surge in demand for insulin as a core treatment drug. At the same time, China Resources Pharmaceutical was also seeking to expand into the biopharmaceutical field. Against this backdrop, China Resources Pharmaceutical signed a strategic agreement in December 2016 to acquire a 20% stake in Tianmai Biotechnology, thus officially entering the ...
- Source: drugdu
- 59
- February 13, 2026
Hanyu Pharmaceutical’s glatiramer acetate injection receives FDA approval in the United States.

Shanghai Securities News China Securities(Reporter He Xinyi) On the evening of February 12, Hanyu Pharmaceutical…The announcement stated that the company received an abbreviated new drug application certificate for glatiramer acetate injection from the U.S. Food and Drug Administration (FDA). The announcement indicates that glatiramer acetate is an immunomodulatory drug used to treat relapsing-remitting multiple sclerosis (MS). It is a synthetic polypeptide preparation that modulates abnormal autoimmune responses by mimicking the structure of myelin basic proteins, thereby reducing the attack on the myelin sheath of the central nervous system. Hanyu Pharmaceutical stated that the approval of glatiramer acetate will further enrich the company’s overseas product pipeline and expand the company’s pharmaceutical market in the United States. The company will actively promote the sales of the drug in overseas markets, thereby positively promoting the company’s future performance growth and industry position. https://finance.eastmoney.com/a/202602123649504078.html
- Source: drugdu
- 65
- February 13, 2026
Global ADC market size $16.5 billion

20 new ADC drugs worldwide reached US$16.51 billion , a year-on-year increase of 27% , maintaining rapid growth. Six of these ADCs are blockbuster products with sales exceeding US$1 billion, including four super blockbuster products with sales exceeding US$2 billion. Enhertu continues to maintain its monopoly position, and its indications continue to expand.Datroway saw a 50% quarter-over-quarter increase and significantly raised its sales forecast.Padcev has performed exceptionally well in the US and European markets, with growth exceeding expectations.Roche’s T-DM1 has maintained steady growth, mainly due to the increase in adjuvant therapy for breast cancer.Polivy maintains rapid growth, solidifies its position as a leading DLBCL provider, and rapidly penetrates the market. Trodelvy is primarily marketed as a second-line treatment for triple-negative breast cancer, with first-line treatment expected to be approved in the second half of this year.Conclusion Chinese ADCs are playing an increasingly important role. BIC’s Trop2 ADC has been approved ...
- Source: drugdu
- 56
- February 13, 2026
A blockbuster hepatitis B drug with sales of 2.4 billion yuan is taking off for the second time.

According to the latest preliminary financial report released by Tebo Bio , the company continued its high growth momentum in 2025, with total operating revenue reaching RMB 3.696 billion, a year-on-year increase of 31.18%; net profit attributable to the parent company was RMB 1.038 billion, a year-on-year increase of 25.39%. This achievement was mainly due to the continued increase in sales volume of its core product, Pegbin , and the incremental contribution brought by the launch of the new product, Yipeisheng . It is worth noting that Pegbin , the company’s flagship product, achieved sales of RMB 2.447 billion in 2024 , with a gross profit margin of an astonishing 96.22% . Building on this already substantial base, stable growth was achieved again in 2025 (the preliminary earnings report did not disclose 2025 sales figures). The surge in popularity of Pegasys is no accident. As the world’s first 40kD polyethylene ...
- Source: drugdu
- 49
- February 13, 2026
【EXPERT Q&A】How can the safety of subjects be guaranteed in drug clinical trials?

Drugdu.com expert’s response: Drug clinical trials are a critical step in evaluating the safety and efficacy of new drugs, with ensuring the safety of trial participants being the foremost principle. To safeguard participant safety, drug clinical trials have established a comprehensive safety assurance system through stringent regulatory oversight, scientifically rigorous design, thorough risk assessment and management, multi-layered protective measures, and continuous ethical review and supervision. The following elaborates on these aspects in detail: 1. Stringent Regulatory and Ethical Requirements Adherence to International Norms: Drug clinical trials must comply with internationally recognized ethical guidelines, such as the Declaration of Helsinki and the Belmont Report, which emphasize principles such as participant protection, informed consent, and risk minimization. Compliance with Domestic Regulations: In China, drug clinical trials must adhere to relevant laws and regulations, including the Good Clinical Practice (GCP) guidelines and the Drug Administration Law. These regulations impose explicit requirements on all ...
- Source: drugdu
- 61
- February 13, 2026
The first patient in the Phase IB/II trial of Verizon’s triple-negative breast cancer was successfully treated.

On February 10, Veolizhibo (09887) announced that the company is pleased to announce that Veolizhibo (PD-L1/4-1BB bispecific antibody opatidisulfimab, LBL-024) has been successfully administered to the first patient in the Phase IB/II trial of recurrent or metastatic triple-negative breast cancer. This trial, led by Professor Yin Yongmei of Jiangsu Provincial People’s Hospital, aims to evaluate the efficacy and safety of opatitumumab alone or in combination with albumin-bound paclitaxel. Verlisin is a bispecific antibody that simultaneously targets PD-L1 and 4-1BB, possessing broad-spectrum cancer treatment potential. In two clinical trials in China, this drug demonstrated promising efficacy and safety in patients with advanced extrapulmonary neuroendocrine carcinoma, whether used as monotherapy or in combination with chemotherapy. In addition, the company received approval from the National Medical Products Administration to conduct a single-arm registration clinical trial in April 2024, obtained Breakthrough Therapy Designation for the treatment of late-line advanced extrapulmonary neuroendocrine carcinoma in October ...
- Source: drugdu
- 64
- February 12, 2026
Watson Bio’s live attenuated varicella vaccine clinical trial approved

Beijing Business Daily , February 10th – Watson BiotechnologyThe company announced that its varicella attenuated live vaccine, jointly developed and applied for clinical trials by the company and its subsidiaries Yunnan Vaccine Laboratory Co., Ltd., Beijing Watson Innovation Biotechnology Co., Ltd., and Yuxi Watson Biotechnology Co., Ltd., recently received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration, agreeing to conduct clinical trials for the prevention of varicella. The announcement indicates that the vaccine is a live attenuated vaccine produced by inoculating human diploid cells with an attenuated strain of varicella-zoster virus and then freeze-drying it. After vaccination, it stimulates the body to produce immunity against the varicella-zoster virus, thus preventing chickenpox. Currently, six companies in China have received marketing authorization for their live attenuated varicella vaccines. https://finance.eastmoney.com/a/202602103646820558.html
- Source: drugdu
- 61
- February 12, 2026
The first subject has been dosed in the Phase II clinical trial of its innovative small nucleic acid drug EDP167.

On February 9, Yiteng Jiahe (06998) issued an announcement, announcing that its innovative small nucleic acid drug…The first subject was successfully dosed in the Phase II clinical trial of EDP167. This trial is aimed at adult patients with homozygous familial hypercholesterolemia (HoFH) and aims to evaluate the efficacy and safety of EDP167 in HoFH patients. The primary endpoint is the change in low-density lipoprotein cholesterol (LDL-C) levels from baseline 24 weeks after the first dose. The evaluation of the primary endpoint is expected to be completed in the fourth quarter of 2026. EDP167 is an innovative siRNA therapy specifically designed to treat dyslipidemia. Its mechanism of action is independent of the LDL receptor pathway, overcoming the limitations of traditional lipid-lowering drugs. Prior to initiating a Phase II clinical trial for HoFH patients, the company completed a Phase I clinical study in healthy individuals and those with mild dyslipidemia. Results showed ...
- Source: drugdu
- 57
- February 12, 2026
Novo Nordisk’s oral weight-loss drug advertisement has been flagged by the FDA for allegedly misleading advertising.

According to the U.S. Food and Drug Administration (FDA), Danish pharmaceutical company Novo Nordisk…For oral weight loss drugsA television advertisement was found to contain “false or misleading” claims. Novo Nordisk is the manufacturer of semaglutide, a drug that is also produced by Eli Lilly.Tirzepatide is a GLP-1 weight loss drug . In January of this year, the oral version of semaglutide was approved for marketing in the United States, becoming the world’s first oral GLP-1 inhibitor for the treatment of obesity. Novo Nordisk stated last week that more than 170,000 patients in the United States are currently using the drug. However, in a letter to Novo Nordisk on February 5, the FDA stated that Novo Nordisk’s advertising for the drug constituted “misbranding,” and therefore its dissemination of the information violated federal law. In its letter, the FDA stated that Novo Nordisk’s advertising was misleading, suggesting that its oral medication was ...
- Source: drugdu
- 55
- February 12, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.